Alkermes hosts investor event to review orexin portfolio and development strategy

Alkermes plc.

Presentation reviewed Alkermes' orexin portfolio on October 9, 2024.
No specific financial or clinical data disclosed in the furnished exhibit.
Investor event focused on development strategy for orexin programs.
Filing under Item 7.01 (Regulation FD) with presentation as Exhibit 99.1.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.